Sadly, hypoglycaemia remains a problematic and not uncommon complication in people with diabetes, particularly in those treated with insulin. It impairs quality of life and can be fatal. Both patients and loved ones are affected and so any approaches to reduce it are helpful. The recent DEVOTE trial, which confirmed that insulin degludec, an ultra-long acting basal insulin, lowered both severe and nocturnal hypoglycaemia by around 40% and 53%, respectively, relative to insulin glargine is therefore to be welcomed.

中文翻译：

---

研究摘要：低血糖症和葡萄糖变异性

令人遗憾的是，低血糖症在糖尿病患者中仍然是一个有问题且并非罕见的并发症，特别是在接受胰岛素治疗的患者中。它会损害生活质量，并可能致命。病人和亲人都会受到影响，因此任何减少它的方法都是有帮助的。最近的DEVOTE试验证实，胰岛素地格曲本（一种超长效基础胰岛素）相对于甘精胰岛素，可分别将重度和夜间低血糖症分别降低40％和53％。